Abstract
Glycogen synthase kinase 3 (GSK-3) inhibitors have aroused a great interest for medicinal chemists and pharmaceutical companies in the last years. In fact, some candidates have reached to clinical trials as disease modifying drugs for Alzheimer’s disease. This review will cover the great improvements recently done in the field of GSK-3 inhibitors switching from random discovery to rational drug design, from full GSK-3 inhibition to mild and controlled activity of enzyme reduction, from unknown therapeutic potential to validated efficacy in different animal models of diseases. Moreover some lessons learnt from clinical trials will be described with the aim to improve future designs. Collective results highlight the importance of mild GSK-3 inhibitors as innovative drugs for severe human unmet diseases.
Keywords: GSK-3 inhibitors, neurodegenerative diseases, Alzheimer’s disease, clinical trials, drug design.
Current Topics in Medicinal Chemistry
Title:Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease
Volume: 13 Issue: 15
Author(s): Ana Martinez, Daniel I. Perez and Carmen Gil
Affiliation:
Keywords: GSK-3 inhibitors, neurodegenerative diseases, Alzheimer’s disease, clinical trials, drug design.
Abstract: Glycogen synthase kinase 3 (GSK-3) inhibitors have aroused a great interest for medicinal chemists and pharmaceutical companies in the last years. In fact, some candidates have reached to clinical trials as disease modifying drugs for Alzheimer’s disease. This review will cover the great improvements recently done in the field of GSK-3 inhibitors switching from random discovery to rational drug design, from full GSK-3 inhibition to mild and controlled activity of enzyme reduction, from unknown therapeutic potential to validated efficacy in different animal models of diseases. Moreover some lessons learnt from clinical trials will be described with the aim to improve future designs. Collective results highlight the importance of mild GSK-3 inhibitors as innovative drugs for severe human unmet diseases.
Export Options
About this article
Cite this article as:
Martinez Ana, Perez I. Daniel and Gil Carmen, Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease, Current Topics in Medicinal Chemistry 2013; 13 (15) . https://dx.doi.org/10.2174/15680266113139990138
DOI https://dx.doi.org/10.2174/15680266113139990138 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Fluoroquinolones: Blessings Or Curses
Current Drug Targets Development and Uses for Monoclonal Antibodies to Chemoattractant Receptors
Current Immunology Reviews (Discontinued) Adeno-Associated Viral Vectors for Retinal Gene Transfer and Treatment of Retinal Diseases
Current Gene Therapy Editorial: Questioning the Governance of Pharmacogenomics and Personalized Medicine for Global Health
Current Pharmacogenomics and Personalized Medicine Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design The Evil Axis of Obesity, Inflammation and Type-2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Acetylcholinesterase Inhibition in Alzheimers Disease
Current Pharmaceutical Design The Human Indoleamine 2,3-Dioxygenase Gene and Related Human Genes
Current Drug Metabolism Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Severe Psychiatric Disorders in Mid-Life and Risk of Dementia in Late- Life (Age 65-84 Years): A Population Based Case-Control Study
Current Alzheimer Research Editorial [Disparity in Pharmacotherapies]
Current Drug Therapy Angiomodulatory and Neurological Effects of Ginsenosides
Current Medicinal Chemistry Message from Editor-in-Chief
CNS & Neurological Disorders - Drug Targets Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets The Yin and Yang of Inflammation
Current Molecular Medicine Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Bleeding Complications in the Course of Treatment with Antidepressants in Elderly Patients
Current Psychiatry Reviews